<p>APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy</p>

Eugene R. Viscusi(Thomas Jefferson University), Neil Singla(Huntington Hospital), Franck Skobieranda(Ionis Pharmaceuticals (United States)), David G. Soergel(Novartis (Switzerland)), David Burt(Social Science Research Solutions (United States)), Emily A. Cook
Journal of Pain Research
March 1, 2019
Cited by 165


Related Papers